CXCL9 as a Reliable Biomarker for Discriminating Anti-IFN-γ-Autoantibody-Associated Lymphadenopathy that Mimics Lymphoma
- PMID: 38153613
- DOI: 10.1007/s10875-023-01643-z
CXCL9 as a Reliable Biomarker for Discriminating Anti-IFN-γ-Autoantibody-Associated Lymphadenopathy that Mimics Lymphoma
Abstract
The diagnosis of adult-onset immunodeficiency syndrome associated with neutralizing anti-interferon γ autoantibodies (AIGA) presents substantial challenges to clinicians and pathologists due to its nonspecific clinical presentation, absence of routine laboratory tests, and resemblance to certain lymphoma types, notably nodal T follicular helper cell lymphoma, angioimmunoblastic type (nTFHL-AI). Some patients undergo lymphadenectomy for histopathological examination to rule out lymphoma, even in the absence of a preceding clinical suspicion of AIGA. This study aimed to identify reliable methods to prevent misdiagnosis of AIGA in this scenario through a retrospective case-control analysis of clinical and pathological data, along with immune gene transcriptomes using the NanoString nCounter platform, to compare AIGA and nTFHL-AI. The investigation revealed a downregulation of the C-X-C motif chemokine ligand 9 (CXCL9) gene in AIGA, prompting an exploration of its diagnostic utility. Immunohistochemistry (IHC) targeting CXCL9 was performed on lymph node specimens to assess its potential as a diagnostic biomarker. The findings exhibited a significantly lower density of CXCL9-positive cells in AIGA compared to nTFHL-AI, displaying a high diagnostic accuracy of 92.3% sensitivity and 100% specificity. Furthermore, CXCL9 IHC demonstrated its ability to differentiate AIGA from various lymphomas sharing similar characteristics. In conclusion, CXCL9 IHC emerges as a robust biomarker for differentiating AIGA from nTFHL-AI and other similar conditions. This reliable diagnostic approach holds the potential to avert misdiagnosis of AIGA as lymphoma, providing timely and accurate diagnosis.
Keywords: CXCL9; IgG4-related lymphadenopathy; adult-onset immunodeficiency; angioimmunoblastic T-cell lymphoma; disseminated nontuberculous mycobacterial infection; multicentric Castleman disease; neutralizing anti-interferon-gamma autoantibody.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- Döffinger R, Helbert MR, Barcenas-Morales G, et al. Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin Infect Dis. 2004;38(1):e10-14. https://doi.org/10.1086/380453 . - DOI - PubMed
-
- Höflich C, Sabat R, Rosseau S, et al. Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood. 2004;103(2):673–5. https://doi.org/10.1182/blood-2003-04-1065 . - DOI - PubMed
-
- Browne SK, Burbelo PD, Chetchotisakd P, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med. 2012;367(8):725–34. https://doi.org/10.1056/NEJMoa1111160 . - DOI - PubMed - PMC
-
- Hong GH, Ortega-Villa AM, Hunsberger S, et al. Natural history and evolution of anti-interferon-γ autoantibody-associated immunodeficiency syndrome in Thailand and the United States. Clin Infect Dis. 2020;71(1):53–62. https://doi.org/10.1093/cid/ciz786 . - DOI - PubMed
-
- Wu UI, Wang JT, Sheng WH, et al. Incorrect diagnoses in patients with neutralizing anti-interferon-gamma-autoantibodies. Clin Microbiol Infect. 2020;26(12):1684.e1-1684.e6. https://doi.org/10.1016/j.cmi.2020.02.030 . - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- MOST 110-2314-B-002-247/National Science and Technology Council
- MOST 111-230-B-002-023/National Science and Technology Council
- MOST 111-2314-B-002-145/National Science and Technology Council
- MOST 112-2320-B-002-040/National Science and Technology Council
- NTUCCS 112-07/National Taiwan University Cancer Center
LinkOut - more resources
Full Text Sources
Medical
Research Materials